Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib resistance or intolerance accelerated-phase chronic myelogenous leukemia
収録刊行物
-
- Blood
-
Blood 111 (4), 1834-1839, 2008